NCT03323710撤回2 期
A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study)
Military Institute od Medicine National Research Institute1 个研究点 分布在 1 个国家开始时间: 2018年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
The study aims to assess antineoplastic efficacy, safety, influence on quality of life and disease-related stress of propranolol taken in combination with sunitinib in previously untreated metastatic renal cell carcinoma
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients are eligible to be included in the study only if they meet all of the following criteria:
- •Histological diagnosis of clear-cell renal cell carcinoma (RCC) or mixed-type RCC with more than 60% of clear-cell component.
- •Diagnosis of stage IV RCC (primary metastatic or recurrence after surgical procedure).
- •Prior nephrectomy (complete or partial).
- •Presence of measurable disease per Response Evaluation Criteria in Solid Tumors version 1.
- •Karnofsky performance status score of 80-100%.
- •Favourable- or intermediate-risk according to Memorial Sloan Kettering Cancer Center criteria.
- •Adequate organ function, including the following:
- •hepatic: total bilirubin ≤ 2 times the upper limit of normal (excluding patients with Gilbert syndrome), aspartate aminotransferase and alanine aminotransferase ≤ 5 times the upper limit of normal,
- •renal: serum creatinine ≤ 2 times the upper limit of normal,
- •bone marrow: absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100000/mm3, hemoglobin ≥ 9.5 g/dl.
- •Normal thyroid function (natural or with supplementation of thyroid hormones) defined as thyroid-stimulating hormone within limits of normal.
- •Age eighteen years or older on the day of consent.
- •Written informed consent prior to study entry.
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •Prior systemic pharmacotherapy of RCC.
- •Treatment with propranolol within 6 months of study entry.
- •Metastases in central nervous system (patients who had central nervous system metastases that were surgically resected and/or treated with radiotherapy in the past and now are without neurological symptoms, are allowed on protocol).
- •Female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods.
- •Presence of other malignancies (patients with carcinoma in situ of the cervix or basal cell carcinoma of the skin are allowed on protocol).
- •Presence of any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
- •heart failure of New York Heart Association Class III or IV, significant cardiac arrhythmia or any other clinically significant cardiovascular disease,
- •unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of entering the study,
- •severely impaired respiration as defined as O2 saturation that is ≤ 90% at rest on room air,
- •uncontrolled diabetes as defined by fasting serum glucose > 1.5 times the upper limit of normal,
- •ejection fraction less than 40% (measured at echocardiography),
- •significant liver disease such as cirrhosis, active hepatitis or chronic persistent hepatitis,
- •active (acute or chronic) infections requiring antimicrobial intervention.
- •Concomitant treatment with:
- •chronic, systemic corticosteroids or another immunosuppressive agent; topical or inhaled corticosteroids are allowed,
- •strong CYP3A4 inducers/inhibitors: carbamazepine, phenytoin, rifabutin, rifampin, nafcillin, phenobarbital, St John's wort, itraconazole, ketoconazole, erythromycin, clarithromycin, nefazodone.
- •Known allergy/sensitivity to sunitinib and/or propranolol.
- •Galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
- •Immunization with attenuated live vaccines within 30 days of study entry.
- •Human immunodeficiency virus sero-positivity at the study entry or in the past.
- •Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of sunitinib and/or propranolol (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
- •Presence of active, bleeding diathesis.
- •Major surgery (defined as requiring general anesthesia) and/or significant traumatic injury (requiring > 28 days to heal) within 28 days of the study entry; presence of side effects due to any surgery or probable requirement of major surgery during the course of the study.
- •Present contraindications to propranolol, that include: bronchial asthma, prolonged fasting, acidosis, hypotension (systolic blood pressure less than 90 mmHg, diastolic blood pressure less than 60 mmHg), severe peripheral arterial circulatory disturbance, cardiogenic shock, bradycardia, Prinzmetal's angina, uncontrolled heart failure, second or third degree heart block, untreated phaeochromocytoma, sick sinus syndrome.
- •Inability or unwillingness of subject or legal guardian/representative to give written informed consent.
研究组 & 干预措施
Propranolol plus Sunitinib
Experimental
干预措施: Propranolol (Drug)
Propranolol plus Sunitinib
Experimental
干预措施: Sunitinib (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: Up to 18 months
Objective Response Rate (ORR) is defined as the percentage of patients who have achieved partial response (PR) or complete response (CR) according to the Response Evaluation Criteria In Solid Tumors (RECIST) v1.1.
次要结局
- Overall Survival (OS)(Up to 18 months)
- Progression-free Survival (PFS)(Up to 18 months)
- Disease Control Rate (DCR)(Up to 18 months)
- Safety profile as assessed by Common Terminology Criteria for Adverse Events v4.03 summarized by type, frequency, and severity.(Up to 18 months)
- Health-related Quality of Life (QoL)(Up to 18 months)
- Disease-related Stress (DRS)(Up to 18 months)
- Tumour tissue and serum biomarkers status(Up to 18 months)
研究者
Paweł Chrom
M.D.
Military Institute od Medicine National Research Institute
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Sunitinib in Treating Patients With Recurrent Malignant GliomasAdult Anaplastic AstrocytomaAdult Diffuse AstrocytomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaAdult OligodendrogliomaAdult Pineal Gland AstrocytomaNCT00499473National Cancer Institute (NCI)31
进行中（未招募）
2 期
Sunitinib for Advanced Thymus Cancer Following Earlier TreatmentThymus NeoplasmsThymomaNCT01621568National Cancer Institute (NCI)56
终止
2 期
Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar CarcinomaHepatocellular CarcinomaFibrolamellar Hepatocellular CarcinomaNCT01215565Assistance Publique - Hôpitaux de Paris4
已完成
2 期
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsPancreatic Neuroendocrine TumorsNCT01121562Pfizer12
已完成
2 期
Sunitinib in Treating Patients With Advanced Malignant Pleural MesotheliomaAdvanced Malignant MesotheliomaRecurrent Malignant MesotheliomaNCT00392444National Cancer Institute (NCI)39